Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867017256432566272 |
|---|---|
| author | Laurence Klotz Tri Tat |
| author_facet | Laurence Klotz Tri Tat Laurence Klotz Tri Tat |
| collection | Wiley Open Access |
| contents | Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies Laurence Klotz Tri Tat BJUI Compass AbstractObjectiveThe objective of the study is to evaluate whether low nadir testosterone during treatment with triptorelin pamoate, a luteinising hormone‐releasing hormone (LHRH) agonist, is associated with improved clinical outcomes in patients with advanced prostate cancer using a retrospective analysis of clinical trial data.Patients and methodsData were pooled from three prospective, 9–12‐month Phase III studies of triptorelin monotherapy in patients with advanced prostate cancer (including NCT00751790). The serum testosterone concentration suppression targets evaluated were <0.35 nmol/L (<10 ng/dl), <0.7 nmol/L (<20 ng/dl), <1.7 nmol/L (<50 ng/dl) and ≥1.7 nmol/L. Overall survival (OS) and disease‐specific survival (DSS) by testosterone suppression group were assessed by Kaplan–Meier analysis, with log‐rank test. The time frame for the primary analysis was Days 1–518 (median OS follow‐up 254 days [range, 29–518 days]) and for the sensitivity analyses was Days 1–262. Supplementary analyses combined the ≥0.7‐ to <1.7‐nmol/L and ≥1.7‐nmol/L groups.ResultsThe sample size comprised 592 patients (most received triptorelin monotherapy; four reported concomitant androgen receptor‐axis–targeted therapy). Nadir testosterones of <0.35, ≥0.35 to <0.7, ≥0.7 to <1.7 and ≥1.7 nmol/L were achieved by 96%, 3.2%, 0.34% and 0.17% of patients, respectively. Better OS with decreasing level of nadir testosterone was observed (p < 0.001) and this persisted after sensitivity/supplemental analyses (all p < 0.001). Differences in DSS with decreasing levels of nadir testosterone were not statistically significant in the primary analysis. Sensitivity/supplemental analysis showed better DSS with decreasing level of nadir testosterone (Days 1–262, p = 0.01; combined groups Days 1–518, p = 0.03; combined groups Days 1–262, p = 0.005).ConclusionLow nadir testosterone achieved during treatment with the LHRH agonist triptorelin was associated with improved OS and DSS in patients with advanced prostate cancer. 10.1002/bco2.318 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/bco2.318 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_bco2_318 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies Laurence Klotz Tri Tat BJUI Compass Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies Laurence Klotz Tri Tat BJUI Compass AbstractObjectiveThe objective of the study is to evaluate whether low nadir testosterone during treatment with triptorelin pamoate, a luteinising hormone‐releasing hormone (LHRH) agonist, is associated with improved clinical outcomes in patients with advanced prostate cancer using a retrospective analysis of clinical trial data.Patients and methodsData were pooled from three prospective, 9–12‐month Phase III studies of triptorelin monotherapy in patients with advanced prostate cancer (including NCT00751790). The serum testosterone concentration suppression targets evaluated were <0.35 nmol/L (<10 ng/dl), <0.7 nmol/L (<20 ng/dl), <1.7 nmol/L (<50 ng/dl) and ≥1.7 nmol/L. Overall survival (OS) and disease‐specific survival (DSS) by testosterone suppression group were assessed by Kaplan–Meier analysis, with log‐rank test. The time frame for the primary analysis was Days 1–518 (median OS follow‐up 254 days [range, 29–518 days]) and for the sensitivity analyses was Days 1–262. Supplementary analyses combined the ≥0.7‐ to <1.7‐nmol/L and ≥1.7‐nmol/L groups.ResultsThe sample size comprised 592 patients (most received triptorelin monotherapy; four reported concomitant androgen receptor‐axis–targeted therapy). Nadir testosterones of <0.35, ≥0.35 to <0.7, ≥0.7 to <1.7 and ≥1.7 nmol/L were achieved by 96%, 3.2%, 0.34% and 0.17% of patients, respectively. Better OS with decreasing level of nadir testosterone was observed (p < 0.001) and this persisted after sensitivity/supplemental analyses (all p < 0.001). Differences in DSS with decreasing levels of nadir testosterone were not statistically significant in the primary analysis. Sensitivity/supplemental analysis showed better DSS with decreasing level of nadir testosterone (Days 1–262, p = 0.01; combined groups Days 1–518, p = 0.03; combined groups Days 1–262, p = 0.005).ConclusionLow nadir testosterone achieved during treatment with the LHRH agonist triptorelin was associated with improved OS and DSS in patients with advanced prostate cancer. 10.1002/bco2.318 http://creativecommons.org/licenses/by/4.0/ |
| title | Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies |
| topic | BJUI Compass |
| url | https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.318 |